ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer
A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.
Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.
Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib
A medical expert navigates toxicity management in patients being treated with ribociclib.
Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema
Dr. Rugo details her management strategy in regards to GI toxicities.
Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients
Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.
Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib
A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.
